Abstract:Taxol (paclitaxel) response is profiled against a panel of clinical missence mutations in β‐tubulin at molecular and cellular levels, aiming to understanding of molecular mechanism and biological implication underlying drug resistance and sensitivity conferring from tubulin mutations. The Paclitaxel‐resistant mutations can be classified into three types, namely nonbonded interaction broken due to mutation, steric hindrance caused by mutation, and conformational change upon mutation. Taxol (paclitaxel) is the first approved microtubule‐stabilizing agent (MSA) by binding stoichiometrically to tubulin, which is considered to be one of the most significant advances in first‐line chemotherapy against diverse tumors. However, a large number of residue missence mutations harboring in the tubulin have been observed to cause acquired drug resistance, largely limiting the clinical application of Taxol and its analogs in chemotherapy. A systematic investigation of the intermolecular interactions between the Taxol and various tubulin mutants would help to establish a comprehensive picture of drug response to tubulin mutations in clinical treatment of cancer, and to design new MSA agents with high potency and selectivity to overcome drug resistance. In this study, we described an integration of in silico analysis and in vitro assay (iSiV) to profile Taxol against a panel of 149 clinically observed, cancer‐associated missence mutations in β‐tubulin at molecular and cellular levels, aiming to a systematic understanding of molecular mechanism and biological implication underlying drug resistance and sensitivity conferring from tubulin mutations. It is revealed that the Taxol‐resistant mutations can be classified into three types: (I) nonbonded interaction broken due to mutation, (II) steric hindrance caused by mutation, and (III) conformational change upon mutation. In addition, we identified three new Taxol‐resistant mutations (C239Y, T274I, and R320P) that can largely reduce the binding affinity of Taxol to tubulin at molecular level, in which the T274I and R320P were observed to considerably impair the antitumor activity of Taxol at cellular level. Moreover, a novel drug‐susceptible mutation (M363T) was also identified, which improves Taxol affinity by 2.6‐fold and decreases Taxol antitumor EC50 values from 29.4 to 18.7 μM.

The mechanical force of minority cells modulates the tumor taxol-resistance and progression

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer

STEM-26. BLOOD-TUMOR BARRIER IS COMPOSED OF MECHANOSENSING TUMOR CELLS THAT MASK THERAPEUTIC VULNERABILITY

Tumor-initiating Stem Cell Shapes Its Microenvironment into an Immunosuppressive Barrier and Pro-Tumorigenic Niche.

Role of the Mechanical Microenvironment in Cancer Development and Progression

Mechano-assisted Strategies to Improve Cancer Chemotherapy

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment

Mechanical-control of cell proliferation increases resistance to chemotherapeutic agents

The tumor microenvironment: a key player in multidrug resistance in cancer

Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line

The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

Targeted mechanical forces enhance the effects of tumor immunotherapy by regulating immune cells in the tumor microenvironment

Cancer Stem Cells and the Tumor Microenvironment in Tumor Drug Resistance

Mechanics and Actomyosin-Dependent Survival/Chemoresistance of Suspended Tumor Cells in Shear Flow

Systematic profiling of Taxol resistance and sensitivity to tubulin missence mutations at molecular and cellular levels

Functions and clinical significance of mechanical tumor microenvironment: cancer cell sensing, mechanobiology and metastasis

MicroRNAs: Key Players of Taxane Resistance and Their Therapeutic Potential in Human Cancers

Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway

Targeting tumor-macrophage interaction via the Notch2-Jag1 axis reverses tumor resistance to paclitaxel